Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna increased its full-year 2026 revenue growth forecast to 15%-25% from a previous target of up to 10% after reporting a surprise third-quarter profit. The revision reflects stronger-than-expected international COVID-19 vaccine sales and early traction for newly approved respiratory syncytial virus and combination vaccines. CEO Stephane Bancel said the newer products are gaining market share. The company beat Q3 earnings estimates, swinging to a profit on higher revenue.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Moderna raised its 2026 revenue growth outlook to 15%-25% from a previous forecast of up to 10%.
- ✓ The company reported a surprise third-quarter profit and beat earnings estimates.
- ✓ CEO Stephane Bancel said newer vaccines are gaining traction in the market.
- ✓ Stronger international COVID-19 vaccine demand contributed to the improved outlook.
What changed
Moderna raised its 2026 revenue growth outlook to 15%-25% from up to 10% and reported a surprise Q3 profit driven by overseas COVID sales and new vaccine uptake.
Live updates
-
Moderna raises 2026 revenue growth outlook to 15%-25% on stronger vaccine demand
Moderna increased its full-year 2026 revenue growth forecast to 15%-25% from a previous target of up to 10% after reporting a surprise third-quarter profit. The revision reflects stronger-than-expected international COVID-19 vaccine sales and early traction for newly approved respiratory syncytial virus and combination vaccines. CEO Stephane Bancel said the newer products are gaining market share. The company beat Q3 earnings estimates, swinging to a profit on higher revenue.
Why it matters
The upgraded guidance signals a faster-than-anticipated transition from pandemic-era COVID boosters to a broader commercial portfolio that includes RSV and flu/COVID combination shots. Investors have debated whether Moderna's pipeline can sustain growth as COVID demand normalizes; the Q3 beat and raised outlook ease some of that skepticism. The profit swing also marks a milestone for the mRNA platform beyond infectious disease.
What is confirmed
- Moderna raised its 2026 revenue growth outlook to 15%-25% from a previous forecast of up to 10%.
- The company reported a surprise third-quarter profit and beat earnings estimates.
- CEO Stephane Bancel said newer vaccines are gaining traction in the market.
- Stronger international COVID-19 vaccine demand contributed to the improved outlook.
- Newly approved RSV and combination vaccines are beginning to contribute to revenue.
What to watch next
- Fourth-quarter 2026 sales data for RSV and combination vaccines to confirm traction durability
- 2027 revenue guidance expected in early 2027 for longer-term growth visibility
- Phase 3 readouts for mRNA cancer vaccine candidate mRNA-4157/V940 in melanoma
confidence 90%Sources used for this update (16)
- www.marketbeat.com — Top Biotech Stocks To Research - October 14th | MarketBeat
- contents.premium.naver.com — [잠옷입고 경제공부] 세계 무역지도를 바꿀 사건!
- www.tradingkey.com — Today’s Market Recap: OpenAI Revenue Concerns; Nasdaq Falls 1.25%, AAOI Drops 13.58%, Brent Gains 4.07%
- digg.com — Microsoft, Alphabet and 14 others object to OKXICE’s tokenized-stock plans · Digg
- www.cnbc.com — Oil today: Iran, US, crude, wti, brent, trump
- CNBC — Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Financial Times — Moderna swings to profit as momentum for cancer vaccine builds
- Reuters — Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
- Seeking Alpha — Moderna to report Q3 amid valuation debate, cancer vaccine results: What to expect (MRNA:NASDAQ)
- 10TV — Moderna: Q3 Earnings Snapshot
- www.cnbc.com — Moderna (MRNA) earnings Q3 2026 - CNBC
- stockalpha.ai — Moderna Raises 2026 Outlook as CEO Says Vaccines - Nov 6
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community